title: What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?
abstract: A 10-year-old boy presents with a history of severe hemophilia A and high-titer inhibitor that had failed high-dose immune tolerance induction (ITI) with a recombinant factor VIII (rFVIII) product and a plasma-derived FVIII product. You are asked by his mother whether he should be tried on ITI with an extended half-life product, in particular, consideration of a rFVIIIFc concentrate.
authors.affiliation: Section of Hematology and Medical Oncology, Department of Internal Medicine, Tulane School of Medicine, New Orleans, LA.
authors.forename: Maissaa
authors.initials: M
authors.lastname: Janbain
authors.affiliation: Division of Pediatric Hematology and Oncology, University of Michigan, Ann Arbor, MI.
authors.forename: Steven
authors.initials: S
authors.lastname: Pipe
mesh_terms: D002648:Child; D005169:Factor VIII / Q000008:administration & dosage / Q000493:pharmacokinetics; D006207:Half-Life; D006467:Hemophilia A / Q000097:blood* / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D008297:Male
chemical_list: C078147:F8 protein, human; D005169:Factor VIII